Cas:21438-66-4 H-Gly-Phe-βNA manufacturer & supplier

Chemical Name:H-Gly-Phe-βNA

CAS.NO:21438-66-4

Synonyms:GLY-PHE β-NAPHTHYLAMIDE

Molecular Formula:C₂₁H₂₁N₃O₂

Molecular Weight:347.41000

HS Code:2924299090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:692.4ºC at 760mmHg

Density:1.254g/cm3

Index of Refraction:1.673

PSA:84.22000

Exact Mass:347.16300

LogP:3.62870

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like GLY-PHE β-NAPHTHYLAMIDE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,GLY-PHE β-NAPHTHYLAMIDE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,GLY-PHE β-NAPHTHYLAMIDE Use and application,GLY-PHE β-NAPHTHYLAMIDE technical grade,usp/ep/jp grade.

Related News: Among them, Zhejiang pharmaceutical companies accounted for 4 of the world’s top ten API manufacturers. H-Gly-Phe-βNA manufacturer The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy. H-Gly-Phe-βNA supplier Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK. H-Gly-Phe-βNA vendor Among them, Zhejiang pharmaceutical companies accounted for 4 of the world’s top ten API manufacturers. H-Gly-Phe-βNA factory The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.